Speaker Lecture Titles
Partial list of confirmed speakers.
| Name | Country | Title |
|---|---|---|
| Liana Apostolova | USA | SPORADIC EARLY-ONSET ALZHEIMER’S DISEASE: RESULTS FROM LEADS |
| Johannes Attems | UK | THE NEUROPATHOLOGICAL ASSESSMENT OF MIXED PATHOLOGY |
| Rhoda Au | USA | REDEFINING ASYMPTOMATIC IN THE DIGITAL ERA |
| Nora Baligacs | Belgium | THE ROLE OF INFLAMMATION AT DIFFERENT STAGES OF ALZHEIMER’S DISEASE |
| Kaj Blennow | Sweden | INTEGRATION OF BLOOD AND CSF BIOMARKERS IN THE DIAGNOSTIC WORKFLOW OF PATIENTS WITH EARLY COGNITIVE SYMPTOMS |
| Mathew Blurton Jones | USA | CNS-WIDE ENGRAFTMENT OF HUMAN MONOCYTES, BUT NOT MICROGLIA, INDUCES A CHRONIC PROINFLAMMATORY STATE, PROMOTING DEMYELINATION, SYNAPTIC LOSS, AND BEHAVIORAL DYSFUNCTION |
| Guojun Bu | Hong-Kong | APOE AND BRAIN LIPID METABOLISM IN AGING AND ALZHEIMER’S DISEASE |
| Luc Buee | France | THE USE OF ANTI-TAU SINGLE DOMAIN ANTIBODIES (VHH) IN DIAGNOSIS AND THERAPY OF TAUOPATHIES |
| Frédéric Checler | France | C99 TOOLS TO FOLLOW ITS AGGREGATION, SPREADING AND TOXICITY |
| Ornit Chiba-Falek | USA | THE SINGLE-CELL LANDSCAPE OF SNCA TRANSCRIPTS ACROSS SYNUCLEINOPATHIES: THERAPEUTIC IMPLICATIONS TOWARDS PRECISION MEDICINE |
| John Collinge | UK | INSIGHTS INTO ALZHEIMER’S DISEASE PHENOTYPE, PATHOGENESIS AND THERAPEUTICS FROM PRION BIOLOGY |
| Claudio A. Cuello | Canada | MULTIFACETED NATURE OF THE PROGRESSIVE CNS TAUOPATHY THROUGH A TRANSGENIC RAT MODEL |
| Bart De Strooper | Belgium | THE CELLULAR PHASE OF ALZHEIMER’S DISEASE |
| Lis de Weerd | Germany | UNDERSTANDING THE ROLE OF MICROGLIA IN ANTIBODY THERAPY IN ALZHEIMER’S DISEASE |
| Marc Diamond | USA | MOLECULAR MECHANISMS OF PROPAGATION OF PATHOLOGY IN TAUOPATHY |
| Daniel Ferreira | Sweden | IMAGING AND FLUID BIOMARKES IN DEMENTIA WITH LEWY BODIES: LATEST RESULTS FROM INTERNATIONAL CONSORTIA |
| Howard Fillit | USA | FROM INNOVATION TO IMPACT: 25+ YEARS OF EVOLUTION IN THE ALZHEIMER’S DRUG PIPELINE AND THE PATH TO COMBINATION THERAPY |
| Adam Fleisher | USA | PROSPECT-ALZ PHASE 2 STUDY OF CEPEROGNASTAT, AN O-GLCNACASE (OGA) INHIBITOR: POST-TREATMENT SAFETY EXTENSION OUTCOMES AND SUBGROUP ASSESSMENTS |
| Juan Fortea | Spain | THE EXPANDING FAMILY OF GENETICALLY DETERMINED AD: ADAD, DSAD, AND APOE4 HOMOZYGOTES |
| Nick Fox | UK | MRI IN A NEW ERA OF DISEASE MODIFYING THERAPIES |
| Dan Frenkel | Israel | ASSESSING THE LINK BETWEEN METABOLIC DISORDER TO PARKINSON'S DISEASE TOWARDS NOVEL THERAPEUTIC INTERVENTION |
| Giovanni Frisoni | Switzerland | FROM PATHOPHYSIOLOGY TO TREATMENT OF ALZHEIMER’S DISEASE: TOWARDS A UNIFYING FRAMEWORK |
| Lutz Frolich | Germany | NOVEL, STANDARDIZED COLLECTION OF ALZHEIMER’S DISEASE BIOMARKERS FROM THE BRAIN-NOSE INTERFACE – RESULTS OF A PILOT CLINICAL TRIAL |
| James Galvin | USA | QUANTIFYING BRAIN HEALTH AS A PREDICTOR OF ALZHEIMER’S RISK, DISEASE PROGRESSION, AND TARGET FOR PREVENTION |
| Angela Genge | Canada | CURRENT CLINICAL TRIALS ALS: FROM SAD TO PIVOTAL PROGRAMS |
| Klaus Gerwert | Germany | MISFOLDING OF ALPHA-SYNUCLEIN ALLOWS STRATIFICATION OF PARKINSON PATIENTS FOR PRECISION THERAPY |
| Ezio Giacobini | Switzerland | TREATMENT OF ALZHEIMER DISEASE : COMBINATION OF IMMUNO- AND CHOLINERGIC THERAPY |
| Gabriel Gold | Switzerland | MICROINFARCTS AND OTHER COMORBIDITIES IN OLD AGE DEMENTIA |
| Todd Golde | USA | CONTEXTUALIZING THE AMYLOID RESPONSOME TO IDENTIFY NOVEL THERAPEUTIC TARGETS |
| Christian Haass | Germany | TREM2 EXPRESSION LEVEL IS CRITICAL FOR MICROGLIAL STATE, METABOLIC CAPACITY AND EFFICACY OF TREM2 AGONISM |
| Oskar Hansson | Sweden | CLINICAL IMPLEMENTATION OF FLUID BIOMARKERS FOR ALZHEIMER’S AND NEURONAL SYNUCLEIN DISEASE |
| Elizabeth Head | USA | ALZHEIMER DISEASE IN PEOPLE WITH DOWN SYNDROME: UPDATES FROM THE ALZHEIMER BIOMARKER CONSORTIUM - DOWN SYNDROME (ABC-DS) |
| Michael Heneka | Luxemburg | INNATE IMMUNE ACTIVATION IN ALZHEIMER’S DISEASE |
| Makato Higuchi | Japan | PROTEINOPATHY IMAGING IN DEMENTIAS AND MOVEMENT DISORDERS: TRANSLATIONAL DEVELOPMENTS FROM ANIMAL MODELS TO HUMANS |
| Henne Holstege | The Netherlands | ESCAPING COGNITIVE DECLINE, AND THE GENETICS BEHIND IT |
| David Holtzman | USA | IDENTIFICATION OF POTENTIAL ANTIGEN PRESENTING CELLS FACILITATING A ROLE FOR ADAPTIVE IMMUNITY IN TAU-MEDIATED NEURODEGENERATION |
| Bradley Hyman | USA | CLUES ABOUT CELL DEATH IN ALZHEIMER DISEASE |
| Costantino Iadecola | USA | NEUROVASCULAR CORRELATES OF ALZHEIMER PATHOLOGY: IMPLICATIONS FOR COGNITIVE HEALTH AND ABETA IMMUNOTHERAPY |
| Ole Isacson | USA | LIPID-DEPENDENT INTERACTIONS OF NEURON AND GLIA APOE VARIANTS WITH ENDOLYSOSOMAL SYSTEMS RELEVANT TO ALZHEIMER’S DISEASE AND RELATED DEMENTIAS |
| Takeshi Iwatsubo | Japan | ROLE OF PLASMA BIOMARKERS IN THE TRIAL READY COHORT AND PATIENT REGISTRY OF ALZHEIMER'S DISEASE |
| Clifford Jack | USA | ADDRESSING CONTROVERSIES WITH REVISED CRITERIA FOR DIAGNOSIS AND STAGING OF ALZHEIMER’S DISEASE |
| William Jagust | USA | LONGITUDINAL PET STUDIES OF TAU ACCUMULATION |
| Joanna Jankowsky | USA | GENE THERAPY USING AΒ VARIANTS FOR AMYLOID REDUCTION |
| Luca Kulic | Switzerland | TRONTINEMAB - FROM EARLY PRECLINICAL GROUNDWORK TO THE CLINICAL VALIDATION OF THE BRAINSHUTTLETM PLATFORM |
| Frank Laferla | USA | MODEL-AD: NEW INSIGHTS AND ADVANCES |
| Seung-Jae Lee | South Korea | INTERPLAY BETWEEN PROTEIN AGGREGATION AND IMMUNITY |
| Virginia Lee | USA | TBA |
| Malcolm Leissring | USA | PROMINENT TAUOPATHY AND INTRACELLULAR AMYLOID ACCUMULATION TRIGGERED BY IMPAIRMENTS IN CATHEPSIN D: EXPLORING A PLAUSIBLE MECHANISTIC LINK BETWEEN AΒ42 AND TAU PROTEOSTASIS |
| Cynthia Lemere | USA | COMPLEMENT, CAA AND ANTI-AMYLOID INDUCED ARIA |
| Frank Longo | USA | SMALL MOLECULE TARGETING OF THE P75 NEUROTROPHIN RECEPTOR MODULATES TAU MECHANISMS IN MOUSE AND HUMAN TRIALS |
| Ken Marek | USA | DEFINING AN EARLY STAGE NSD POPULATION FOR PATH TO PREVENTION IN PPMI |
| Pamela McLean | USA | CELLULAR RESPONSE TO ALPHA-SYNUCLEIN AGGREGATION |
| Mirek Brys | USA | TARGETING TAU IN ALZHEIMER’S DISEASE: LESSONS FROM BIOMARKER AND CLINICAL ASSESSMENT INTERACTIONS IN PROSPECT-ALZ, PHASE 2 STUDY OF CEPEROGNASTAT |
| Daniel M. Michaelson | Israel | THE ROLE OF LIPIDS IN MEDIATING APOE4 DRIVEN PATHOLOGY |
| Michelle Mielke | USA | EXPERIENCE WITH IMPLEMENTING COGNITIVE TESTING AND BLOOD-BASED AD BIOMARKERS IN PRIMARY CARE PRACTICES |
| Thomas Montine | USA | GLUTAMATERGIC FALSE NEUROTRANSMITTER PROMOTES RESISTANCE TO PATHOLOGIC TAU ACCUMULATION IN MICE |
| Asuka Morizane | Japan | CELL THERAPY FOR PARKINSON’S DISEASE WITH ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS. |
| John Morris | USA | EARLY LIFE EXPERIENCES AND CURRENT STRESS INFLUENCE FLUID BIOMARKERS OF ALZHEIMER DISEASE |
| Ulrike Müller | Germany | INSIGHTS FROM NOVEL SECRETION DEFICIENT APP KNOCKIN MICE LACKING THE ALPHA- AND BETA-SECRETASE SITES |
| Melissa Murray | USA | PHENOTYPIC MANIFESTATIONS OF R406W MAPT MUTATION CARRIERS |
| Henrietta Nielsen | Sweden | APOE HEPATIC SIGNATURES AND RELEVANCE TO THE BRAIN |
| Agneta Nordberg | Sweden | INTERACTION OF KIN83 , A NOVEL ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR SELECTIVE PET RADIOTRACER. WITH REACTIVE ASTROCYTES AND SOLUBLE FORMS OF Aß IN ALZHEIMER BRAINS |
| Kate Onuska | Canada | MOLECULAR CHOLINERGIC DEFICITS UNDERLIE CORTICAL PATHOLOGY IN PRESYMPTOMATIC ALZHEIMER'S DISEASE |
| Anja Ophey | Germany | SUBJECTIVE COGNITIVE DECLINE IN INDIVIDUALS WITH ISOLATED REM SLEEP BEHAVIOR DISORDER: CHARACTERIZATION, NEUROPSYCHOLOGICAL CORRELATES, AND STRUCTURAL BRAIN CHANGES |
| Tiago Outerio | Germany | MODULATION OF EPITRANSCRIPTOMICS BY ALPHA-SYNUCLEIN: NOVEL INSIGHT INTO THE PARKINSON'S DISEASE |
| Ronald Petersen | USA | ALZHEIMER’S DISEASE DIAGNOSIS IN THE COMMUNITY |
| Werner Poewe | Austria | TOWARDS A BIOLOGICAL DEFINITION OF PD - THE ROLE OF NEUROIMAGING |
| Marco Prado | Canada | EARLY DYSREGULATION OF CHOLINERGIC SIGNALLING IN ALZHEIMER’S DISEASE |
| Laura Ranum | USA | REPEAT ASSOCIATED NON-AUG PROTEINS IN NEUROLOGIC DISEASE: MECHANISTIC AND THERAPEUTIC INSIGHTS FROM ALZHEIMER’S DISEASE AND C9ORF72 ALS/FTD |
| Stephen Salloway | USA | APPROPRIATE USE OF AMYLOID-LOWERING TREATMENTS |
| Philip Scheltens | Netherlands | A VIEW FROM THE VENTURE SIDE: WHAT IS HOT IN NEURODEGENERATION? |
| Sjors Scheres | UK | HOW CRYOEM STRUCTURES OF TAU FILAMENTS INFORM NEW DISEASE MODELS |
| Michael Schlossmacher | Canada | TO FOLLOW THE NOSE: CLINICOPATHOLOGICAL EXAMINATION OF THE OLFACTORY CIRCUITRY IN TYPICAL PARKINSON’S |
| Taylor Schmitz | Canada | SPATIAL PROFILES OF CORTICAL CHOLINERGIC SYNAPTIC DYSFUNCTION COLOCALIZE TAU AGGREGATION |
| Julia Schumacher | Germany | NEUROPATHOLOGICAL CORRELATES OF BASAL FOREBRAIN ATROPHY IN ALZHEIMER’S AND LEWY BODY DISEASE |
| Menachem Segal | Israel | MITOCHONDRIAL CALCIUM AND PRESENILIN INVOLVEMENT IN ALZHEIMER’S DISEASE PROGRESSION |
| Jung-Hwan Shin | South Korea | SPATIOTEMPORAL PATTERNS OF NEURAL ENSEMBLE IN THE PARKINSONIAN STRIATAL NETWORK |
| Tamara Shiner | Israel | ANTI-AMYLOID THERAPIES IN ALZHEIMER’S DISEASE: REAL-WORLD EXPERIENCE |
| Sam Sisodia | USA | SEX-SPECIFIC MODULATION OF AD-TYPE PATHOLOGY BY PERTURBATIONS OF THE GUT MICROBIOME |
| Beka Solomon | Israel | THERAPEUTIC POTENTIAL OF BONE MARROW–DERIVED MICROGLIA IN ALZHEIMER’S DISEASE |
| Mona Soreq | Israel | PRE-SYMPTOMATIC BLOOD CELLS DIAGNOSIS OF PARKINSON’S DISEASE-ESCALATED MOTIF-SHARING TRANSFER RNA FRAGMENTS DECLINED UNDER DEEP BRAIN STIMULATION |
| Maria Grazia Spillantini | UK | EFFECT OF TAU AGGREGATION ON GLIAL CELLS |
| Peter St. George-Hyslop | Canada | CD33 SIGNALLING IN MICROGLIA |
| Beth Stevens | USA | PRE-RECORDED: NEUROIMMUNE RESPONSE IN CNS AND PERIPHERY TO AD PATHOLOGY IN A RARE DISEASE COHORT |
| Fabrizio Stocchi | Italy | HOW THE THERAPEUTIC APPROACH TO EARLY PARKINSON’S DISEASE WILL CHANGE IN THE NEXT FUTURE |
| Tom Sudhof | USA | LIPID METABOLISM IN ALZHEIMER’S DISEASE |
| Malu Tansey | USA | ROLE OF CHRONIC PERIPHERAL INFLAMMATION AND IMMUNE DYSFUNCTION IN AGE-RELATED NEURODEGENERATION |
| Rudy Tanzi | USA | DRUG AND NATURAL PRODUCT REPURPOSING FOR THE TREATMENT OF ALZHEIMER’S DISEASE |
| Niccolo Tesi | The Netherlands | GENETIC MECHANISMS UNDERLYING ALZHEIMER’S DISEASE RISK AND RESISTANCE |
| Li-Huei Tsai | USA | ALZHEIMER’S DISEASE RISK GENE APOE4 DRIVES PERTURBATIONS IN THE GLOBAL LIPID ECONOMY OF THE BRAIN AND CEREBROSPINAL FLUID |
| Wei Tsai | USA | PRECISION BIOMARKERS FOR NEURODEGENERATIVE DISEASES |
| Vivek Unni | USA | LINKING PARKINSON'S DISEASE AND MELANOMA: ALPHA-SYNUCLEIN IN NUCLEOLAR DNA DOUBLE-STRAND BREAK REPAIR |
| Robert Vassar | USA | BACE INHIBITION FOR ALZHEIMER’S DISEASE |
| Michael Weiner | USA | THE ADNI4 APPROACH FOR INCREASING DIVERSITY IN AD CLINICAL TRIALS |
| Cheryl Wellington | Canada | LEVERAGING MULTIPLE CANADIAN COHORTS FOR ALZHEIMER’S DISEASE PLASMA BIOMARKER STUDIES |
| Donna Wilcock | USA | A PIVOTAL ROLE FOR INFLAMMATION AND MMP9 IN ANTI-AMYLOID-INDUCED ARIA |
| Bengt Winblad | Sweden | PROTAC: A NOVEL STRATEGY FOR THE TREATMENT OF ALZHEIMER DISEASE |
| Manfred Windisch | Austria | PLEIOTROPIC EFFECTS OF THE CNS-SELECTIVE M1 MUSCARINIC AGONIST NSC001: FROM FAST SYMPTOMATIC ACTIVITY TO LONG-TERM DISEASE MODIFICATION IN AD |
| Tony Wyss-Coray | USA | PROTEOMIC STUDIES TO UNDERSTAND BRAIN AGING AND NEURODEGENERATION |
| Henrik Zetterberg | Sweden | SIMPLIFIED DIAGNOSTICS OF NEURODEGENERATIVE DEMENTIAS USING MULTIPLEXED ULTRASENSITIVE IMMUNOASSAYS |
| Dimitri Krainc | USA | CONVERGENCE OF MITOCHONDRIAL AND LYSOSOMAL PATHWAYS IN NEURODEGENERATIVE DISEASES |
| Sid O'Bryant | USA | ALZHEIMER’S DISEASE BIOMARKERS AMONG DIVERSE POPULATIONS – FINDINGS FROM THE HABS-HD STUDY |
| Berislav Zlokovik | USA | TARGETING THE BLOOD-BRAIN BARRIER FOR TREATMENT OF NEURONAL DYSFUNCTION AND ALZHEIMER’S’ PATHOLOGY |